compounded semaglutide crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Despite FDA crackdown, unapproved GLP-1s

These modifications are designed to enhance T-cell proliferation and survival, thereby improving clinical outcomes

40% off with annual subscription Set your research on autopilot

These data can be found at Conflicts of Interest The authors declare no conflicts of interest

Oral Tablet/Capsule Segment is Expected to Drive the Next-generation Obesity Drug Pipeline Market The Oral Tablet/Capsule category held the largest share in the Next-generation Obesity Drug Pipeline market in 2025 driven by the increasing need for treatment solutions that are more patient-friendly and convenient

You get the strong, sustained signal from Tesamorelin combined with the clean, targeted pulse from Ipamorelin (a highly selective GHRP)

CMS is launching this demonstration project on July 1, and it will provide access to a limited selection of GLP-1 weight loss drugs to eligible Medicare Part D beneficiaries